ArticleCurrent therapeutic research, clinical and experimental2026
Almost Three Decades of Post-Marketing Experience With A Human Intravenous Immunoglobulin 5%: Analysis of A Propriety Pharmacovigilance Database.
Davide Susini et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.